HIVE Earnings

HIVE reported its earnings on 2025-11-14, showcasing a revenue of against an estimate of 80.37M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.01 by 0%. The stock experienced a -9.56% price change on the earnings day and a -15.85% change over the next five days, reflecting market reactions to the results.

Following HIVE's earnings announcement on 2025-11-14, the stock price moved by -9.56% on the day of the release. Over the subsequent five days, it saw a -15.85% change. Historically, HIVE's stock price tends to shift by an average of 13.29% in the 10 days leading up to earnings and -2.48% in the 10 days following, providing insight into potential market.

For 2026/Q4, analysts estimate HIVE's annual revenue to reach 101.83M, while the EPS is projected at -0.08. These estimates reflect recent revisions, with revenue estimates revised downward by -0.72% and EPS estimates revised upward by 0.18% over the past three months, indicating analyst expectation in the company's performance.

The correlation between HIVE's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2026 were revised downward by -0.72%, while EPS estimates moved revised upward by 0.18%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, HIVE's stock price typically moves by 13.29% in the 10 days before its earnings and -2.48% in the 10 days after. For the upcoming 2026/Q4 earnings, analysts expect an EPS of -0.08 and revenue of 101.83M.

The earnings call showed strong financial performance with significant revenue growth, improved margins, and increased Bitcoin production. The strategic partnership with Bell Canada and plans for expansion in AI and HPC sectors are promising. Despite a net loss due to noncash charges, future guidance is optimistic. The Q&A session confirmed robust demand for GPUs and strategic capital allocation, enhancing growth prospects. However, management's reluctance to provide specific details on CapEx for the New Brunswick facility slightly tempers the outlook, but overall, the sentiment remains positive.